Market Research Logo

Rosacea - Epidemiology Forecast-2027

DelveInsight’s ‘Rosacea - Epidemiology Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Rosacea in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Rosacea - Disease Understanding and Treatment Algorithm

The DelveInsight Rosacea market report gives the thorough understanding of the Rosacea by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Rosacea in the US, Europe, and Japan.

Rosacea Epidemiology

The Rosacea epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Prevalent population, Gender specific prevalence, Diagnosed prevalent population, Sub-type specific diagnosed prevalence and Severity-Specific diagnosed prevalence] scenario of Rosacea in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total prevalent population of Rosacea was found to be 47,359,758, in the year 2016.

Rosacea Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
The disease epidemiology covered in the report is segmented by Gender-specific [Male and Female] and severity specific.

Report Scope

• The report covers detailed overview of Rosacea explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of rosacea
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by gender and sub-types in 7MM

Rosacea Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Rosacea Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake

Rosacea Report Assessment

• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Rosacea market
• Organize sales and marketing efforts by identifying the best opportunities for Rosacea market
• To understand the future market competition in the Rosacea market.


1. Key Insights
2. Rosacea: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Rosacea in 2016
2.2. Total Market Share (%) Distribution of Rosacea in 2027
3. Disease Background and Overview: Rosacea
3.1. Introduction
3.2. Signs and Symptoms
3.3. Classification of Rosacea
3.4. Stages and GRADE
3.5. Pathophysiology
3.6. Genetic Basis of Rosacea according to Genome-Wide Association Study
3.7. Causes and Risk factors for Rosacea
3.8. Risk Factors
3.9. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
5. 7MM Total Prevalent Patient Population of Rosacea
6. 7MM Total Diagnosed Prevalent Patient Population of Rosacea
7. Country Wise-Epidemiology of Rosacea Disease
7.1. United States
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Population of Rosacea in the United States
7.1.3. Gender-Specific Prevalent Population of Rosacea in the United States
7.1.4. Total Diagnosed Prevalent Population of Rosacea in the United States
7.1.5. Sub – Type Specific Diagnosed Prevalence of Rosacea in the United States
7.1.6. Severity – Specific Diagnosed Prevalent Population of Rosacea in United States
7.2. EU5 Countries
7.2.1. Assumptions and Rationale
7.3. Germany
7.3.1. Total Prevalent Population of Rosacea in Germany
7.3.2. Gender-Specific Prevalent Population of Rosacea in Germany
7.3.3. Total Diagnosed Prevalent Population of Rosacea in Germany
7.3.4. Sub – Type Specific Diagnosed Prevalence of Rosacea in Germany
7.3.5. Severity – Specific Diagnosed Prevalent Population of Rosacea in Germany
7.4. France
7.4.1. Total Prevalent Population of Rosacea in France
7.4.2. Gender-Specific Prevalent Population of Rosacea in France
7.4.3. Total Diagnosed Prevalent Population of Rosacea in France
7.4.4. Sub – Type Specific Diagnosed Prevalence of Rosacea in France
7.4.5. Severity – Specific Diagnosed Prevalent Population of Rosacea in France
7.5. Italy
7.5.1. Total Prevalent Population of Rosacea in Italy
7.5.2. Gender-Specific Prevalent Population of Rosacea in Italy
7.5.3. Total Diagnosed Prevalent Population of Rosacea in Italy
7.5.4. Sub – Type Specific Diagnosed Prevalence of Rosacea in Italy
7.5.5. Severity – Specific Diagnosed Prevalent Population of Rosacea in Italy
7.6. Spain
7.6.1. Total Prevalent Population of Rosacea in Spain
7.6.2. Gender-Specific Prevalent Population of Rosacea in Spain
7.6.3. Total Diagnosed Prevalent Population of Rosacea in Spain
7.6.4. Sub – Type Specific Diagnosed Prevalence of Rosacea in Spain
7.6.5. Severity – Specific Diagnosed Prevalent Population of Rosacea in Spain
7.7. United Kingdom
7.7.1. Total Prevalent Population of Rosacea in the United Kingdom
7.7.2. Gender-Specific Prevalent Population of Rosacea in the United Kingdom
7.7.3. Total Diagnosed Prevalent Population of Rosacea in the United Kingdom
7.7.4. Sub – Type Specific Diagnosed Prevalence of Rosacea in the United Kingdom
7.7.5. Severity-Specific Diagnosed Prevalent Population of Rosacea in United Kingdom
7.8. Japan
7.8.1. Assumptions and Rationale
7.8.2. Total Prevalent Population of Rosacea in Japan
7.8.3. Gender-Specific Prevalent Population of Rosacea in Japan
7.8.4. Total Diagnosed Prevalent Population of Rosacea in Japan
7.8.5. Sub – Type Specific Diagnosed Prevalence of Rosacea in Japan
7.8.6. Severity – Specific Diagnosed Prevalent Population of Rosacea in Japan
8. Appendix
8.1. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables and Figures
Table 1: Total Prevalent Population of Rosacea in the 7MM (2016-2027)
Table 2: Total Diagnosed Prevalent Population of Rosacea in the 7MM (2016-2027)
Table 3: Total Prevalent Population of Rosacea in the United States (2016-2027)
Table 4: Gender Specific Prevalence of Rosacea in the United States (2016-2027)
Table 5: Diagnosed Prevalence of Rosacea in the United States (2016-2027)
Table 6: Sub- type Specific Diagnosed Prevalence of Rosacea in the United States (2016-2027)
Table 7: Severity-Specific Diagnosed Prevalence of Rosacea in the United States (2016-2027)
Table 8: Total Prevalent Population of Rosacea in Germany (2016-2027)
Table 9: Gender Specific Prevalence of Rosacea in Germany (2016-2027)
Table 10: Total Diagnosed Prevalent Population of Rosacea in Germany (2016-2027)
Table 11: Sub-Type Specific Diagnosed Prevalence of Rosacea in Germany (2016-2027)
Table 12: Severity-Specific Diagnosed Prevalence of Rosacea in Germany (2016-2027)
Table 13: Total Prevalent Population of Rosacea in France (2016-2027)
Table 14: Gender Specific Prevalence of Rosacea in France (2016-2027)
Table 15: Total Diagnosed Prevalent Population of Rosacea in France (2016-2027)
Table 16: Sub-Type Specific Diagnosed Prevalence of Rosacea in France (2016-2027)
Table 17: Severity-Specific Diagnosed Prevalence of Rosacea in France (2016-2027)
Table 18: Total Prevalent Population of Rosacea in Italy (2016-2027)
Table 19: Gender Specific Prevalence of Rosacea in Italy (2016-2027)
Table 20: Total Diagnosed Prevalent Population of Rosacea in Italy (2016-2027)
Table 21: Sub-Type Specific Diagnosed Prevalence of Rosacea in Italy (2016-2027)
Table 22: Severity-Specific Diagnosed Prevalence of Rosacea in Italy (2016-2027)
Table 23: Total Prevalent Population of Rosacea in Spain (2016-2027)
Table 24: Gender Specific Prevalence of Rosacea in Spain (2016-2027)
Table 25: Total Diagnosed Prevalent Population of Rosacea in Spain (2016-2027)
Table 26: Sub-Type Specific Diagnosed Prevalence of Rosacea in Spain (2016-2027)
Table 27: Severity-Specific Diagnosed Prevalence of Rosacea in Spain (2016-2027)
Table 28: Total Prevalent Population of Rosacea in the UK (2016-2027)
Table 29: Gender Specific Prevalence of Rosacea in the UK (2016-2027)
Table 30: Total Diagnosed Prevalent Population of Rosacea in the UK (2016-2027)
Table 31: Sub-Type Specific Diagnosed Prevalence of Rosacea in the UK (2016-2027)
Table 32: Severity-Specific Diagnosed Prevalence of Rosacea in the United Kingdom (2016-2027)
Table 33: Total Prevalent Population of Rosacea in Japan (2016-2027)
Table 34: Gender Specific Prevalence of Rosacea in Japan (2016-2027)
Table 35: Total Diagnosed Prevalent Population of Rosacea in Japan (2016-2027)
Table 36: Sub-Type Specific Diagnosed Prevalence of Rosacea in Japan (2016-2027)
Table 37: Severity-Specific Diagnosed Prevalence of Rosacea in Japan (2016-2027)
Figure 1: Signs and Symptoms of Rosacea
Figure 2: Clinical manifestations of Rosacea
Figure 3: Different forms of Rosacea.
Figure 4: Selective receptor activation by rosacea triggers determining phenotypic outcomes
Figure 5: Proposed adaptive pathophysiological pathways in rosacea
Figure 6: Potential pathophysiology of rosacea integrating clinical, immunological, neurovascular, and molecular characteristics.
Figure 7: Potential role of neurogenic inflammation in the early phase of rosacea.
Figure 8: Neurovascular transient receptor potential (TRP) vanilloid receptor 1 (TRPV1) hypothesis in rosacea.
Figure 9: Schematic view of the factors known to contribute to the molecular mechanisms of rosacea.
Figure 10: Primary pathogenic targets in rosacea with their respective treatment options.
Figure 11: Representation of proposed mechanisms for rosacea.
Table 12: Differential diagnosis of Rosacea
Figure 13: Total Prevalent Population of Rosacea in the 7MM (2016-2027)
Figure 14: Total Diagnosed Prevalent Population of Rosacea in the 7MM (2016-2027)
Figure 15: Total Prevalent Population of Rosacea in the United States (2016-2027)
Figure 16: Gender Specific Prevalence of Rosacea in the United States (2016-2027)
Figure 17: Diagnosed Prevalence of Rosacea in the United States (2016-2027)
Figure 18: Sub-Type Specific Diagnosed Prevalence of Rosacea in the United States (2016-2027)
Figure 19: Severity-Specific Diagnosed Prevalence of Rosacea in the United States (2016-2027)
Figure 20: Total Prevalent Population of Rosacea in Germany (2016-2027)
Figure 21: Gender Specific Prevalence of Rosacea in Germany (2016-2027)
Figure 22: Total Diagnosed Prevalent Population of Rosacea in Germany (2016-2027)
Figure 23: Sub-Type Specific Diagnosed Prevalence of Rosacea in Germany (2016-2027)
Figure 24: Severity-Specific Diagnosed Prevalence of Rosacea in Germany (2016-2027)
Figure 25: Total Prevalent Population of Rosacea in France (2016-2027)
Figure 26: Gender Specific Prevalence of Rosacea in France (2016-2027)
Figure 27: Total Diagnosed Prevalent Population of Rosacea in France (2016-2027)
Figure 28: Sub-Type Specific Diagnosed Prevalence of Rosacea in France (2016-2027)
Figure 29: Severity-Specific Diagnosed Prevalence of Rosacea in France (2016-2027)
Figure 30: Total Prevalent Population of Rosacea in Italy (2016-2027)
Figure 31: Gender Specific Prevalence of Rosacea in Italy (2016-2027)
Figure 32: Total Diagnosed Prevalent Population of Rosacea in Italy (2016-2027)
Figure 33: Sub-Type Specific Diagnosed Prevalence of Rosacea in Italy (2016-2027)
Figure 34: Severity-Specific Diagnosed Prevalence of Rosacea in Italy (2016-2027)
Figure 35: Total Prevalent Population of Rosacea in Spain (2016-2027)
Figure 36: Gender Specific Prevalence of Rosacea in Spain (2016-2027)
Figure 37: Total Diagnosed Prevalent Population of Rosacea in Spain (2016-2027)
Figure 38: Sub-Type Specific Diagnosed Prevalence of Rosacea in Spain (2016-2027)
Figure 39: Severity-Specific Diagnosed Prevalence of Rosacea in Spain (2016-2027)
Figure 40: Total Prevalent Population of Rosacea in the UK (2016-2027)
Figure 41: Gender Specific Prevalence of Rosacea in the UK (2016-2027)
Figure 42: Total Diagnosed Prevalent Population of Rosacea in the UK (2016-2027)
Figure 43: Sub-Type Specific Prevalence of Rosacea in the UK (2016-2027)
Figure 44: Severity-Specific Diagnosed Prevalence of Rosacea in the UK (2016-2027)
Figure 45: Total Prevalent Population of Rosacea in Japan (2016-2027)
Figure 46: Gender Specific Prevalence of Rosacea in Japan (2016-2027)
Figure 47: Total Diagnosed Prevalent Population of Rosacea in Japan (2016-2027)
Figure 48: Sub-Type Specific Diagnosed Prevalence of Rosacea in Japan (2016-2027)
Figure 49: Severity-Specific Diagnosed Prevalence of Rosacea in Japan (2016-2027)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report